Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Informe acción SEHK:2315
Capitalización de mercado: HK$2.3b
Salud financiera de hoja de balance de Biocytogen Pharmaceuticals (Beijing)
Salud financiera controles de criterios 4/6 Biocytogen Pharmaceuticals (Beijing) tiene un patrimonio de los accionistas total de CN¥744.2M y una deuda total de CN¥395.5M, lo que sitúa su ratio deuda-patrimonio en 53.1%. Sus activos y pasivos totales son CN¥2.4B y CN¥1.7B respectivamente.
Información clave
53.1%
Ratio deuda-patrimonio
Ratio de cobertura de intereses n/a Efectivo CN¥424.07m Patrimonio CN¥744.24m Total pasivo CN¥1.69b Activos totales CN¥2.43b
Actualizaciones recientes sobre salud financiera
Mostrar todas las actualizaciones
First half 2024 earnings released: CN¥0.13 loss per share (vs CN¥0.48 loss in 1H 2023) Sep 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Q2, 2024 Results on Aug 28, 2024 Aug 16
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment? May 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking Apr 03
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Annual General Meeting, May 28, 2024 Mar 28
Full year 2023 earnings released: CN¥0.96 loss per share (vs CN¥1.58 loss in FY 2022) Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
New minor risk - Share price stability Feb 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Approves Election of Ms. Li Yan as A Non-Employee Representatives Supervisor of the Company Dec 13
New minor risk - Share price stability Oct 06
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs Sep 15
Forecast to breakeven in 2025 Aug 31
First half 2023 earnings released: CN¥0.48 loss per share (vs CN¥0.73 loss in 1H 2022) Aug 30
New minor risk - Profitability Aug 29
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth Aug 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023 Aug 16
Forecast to breakeven in 2025 Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 28
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Launches Rennano Mouse, Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery Dec 30
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces FDA Clearance of IND Application for Bispecific Antibody YH008 Dec 19
Less than half of directors are independent Nov 16
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Management Appointments Nov 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Announces Resignation of Huang Xiaolu as Non-Executive Director and A Member of the Strategy Development Committee Oct 18
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. to Present at Biojapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress Sep 28
First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021) Sep 27
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has completed an IPO in the amount of HKD 548.74937 million. Sep 01
Less than half of directors are independent Sep 01
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥766.1M) de 2315 superan a sus pasivos a corto plazo (CN¥572.6M).
Pasivo a largo plazo: Los activos a corto plazo (CN¥766.1M) de 2315 no cubren sus pasivos a largo plazo (CN¥1.1B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 2315 tiene más efectivo que su deuda total.
Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de 2315 se ha reducido en los últimos 5 años.
Análisis de cash runway En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: 2315 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: 2315 dispone de suficiente cash runway para 1.5 años si el flujo de caja libre sigue creciendo a tasas históricas de 35.5% cada año.
Descubre empresas con salud financiera Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
